GlobalData on MSN1d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
Clinical Trials Arena on MSN13d
Persica’s antibiotic-based drug alleviates lower back pain in Phase Ib trial
Evidence has shown that 25% of patients with chronic lower back pain could be suffering from an infection in the disc space.
The Pharma Letter2d
Eneboparatide met primary Phase III endpoint, says AstraZeneca
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Clinical Trials Arena on MSN12d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trial
Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but ...